2026 PharmDev Roadmap: The Regulatory Shift
Frederik Deroose
on
March 3, 2026
Over the course of this series, we have examined how supply chain fragmentation, complexity, predictive models, and distributed partnerships are reshaping pharmaceutical development and manufacturing (PharmDev). Together, these shifts point to an operating environment that is more specialized, interconnected, and knowledge-driven than ever before.
As development models change, regulatory requirements are evolving alongside them. As we wrap up our 2026 roadmap series, we will explore how FDA and EMA expectations are shifting within the PharmDev landscape.
The Regulatory Shift – FDA and EMA Expectations for New Modalities
Across FDA and EMA expectations, the industry is seeing a rise in the importance of process understanding supported by structured data. Demonstrating product quality is still foundational, but approval pathways increasingly reflect confidence in how well sponsors understand variability, control strategies, and lifecycle knowledge. Programs are expected not only to perform, but to demonstrate why their performance is reliable.
Last year’s update to the FDA guidance on the use of artificial intelligence to support regulatory decision-making reflects growing attention to the credibility, structure, and traceability of data generated across PharmDev, which reflects a broader regulatory preference for approaches that:
- Document process understanding
- Show clear control strategies across the development and manufacturing lifecycle
- Demonstrate structured and accessible data
- Reduce reliance on processes that are controlled through testing, rather than understanding
In practice, these expectations are beginning to surface across a range of therapeutic modalities and manufacturing approaches.
Where the Shift Becomes Visible
In small molecules, increased interest in continuous manufacturing, process analytical technologies, and real-time release approaches are proof of this shift. Regulatory openness to these models is largely shaped by the depth of process understanding that supports them. Here, the adoption of new innovations in PharmDev is tied to the ability to explain and control them. Biologics and advanced therapies are experiencing similar requirements as comparability expectations, platform assumptions, and manufacturing changes occurring under accelerated timelines all reinforce the need for documented understanding and well-defined control strategies.
As discussed in The Complexity Spike, personalized therapies are increasingly challenging the traditional evidence models that were built for larger, more uniform datasets. Recent FDA guidance describing the use of a plausible mechanism framework for personalized medicine reflects an expectation that these approaches are supported by clear scientific reasoning, even when conventional data packages are limited. Here as well, regulatory flexibility is closely linked to the clarity of the scientific and manufacturing story supporting the therapeutic.
Across therapeutic modalities, innovation and regulatory requirements are evolving together. For both sponsors and suppliers, this reinforces that cutting-edge innovation must be accompanied by evidence of process understanding and change control.
Distributed Development and Regulatory Coherence
As discussed throughout the series, the industry is responding to increased complexity by shifting to specialized, and thus distributed, operating models. This is not without increased regulatory complexity. As sponsors increasingly engage multiple CDMOs across process development, drug substance, and drug product manufacturing, regulatory narratives must remain coherent despite operational and geographical distribution. Key areas where this is especially challenging include:
- Maintaining data continuity across organizations
- Documenting consistency and traceability
- Aligning change management between contributors
- Differentiating between who performs an activity and who is accountable to regulators
While execution responsibilities are distributed in this model, regulatory accountability remains with the sponsor. The ability for a supplier to integrate therefore becomes as important as their technical capability. This reinforces the importance of GMP maturity across distributed partners, where consistency in quality systems, documentation practices, and change control supports a coherent regulatory position.
Updated EMA Variations Guidelines, which became effective for submissions beginning in January 2026, are intended to streamline post-approval changes through a more risk-based framework that supports grouped submissions, worksharing, and simplified classification of low-risk changes. In practice, these changes acknowledge that modern development programs generate frequent manufacturing and process adjustments, often occurring across multiple contributors. The regulatory response is not to constrain change, but to structure it in a way that preserves coherence despite this increased complexity.
For sponsors, this reinforces the need to plan change proactively and maintain a coherent strategy across partners. For CDMOs, it elevates the importance of transparent change communication and documentation that can integrate easily into a sponsor’s regulatory narrative.
Our System is Evolving, Not Breaking
Regulatory evolution is mirroring the shift of PharmDev itself: fragmentation has expanded global supply networks, modality complexity has increased technical requirements, predictive approaches allow us to learn earlier in development, and orchestration is becoming necessary to coordinate across networks of highly-specialized partners.
Expectations are rising not as a barrier to progress, but as a reflection of a PharmDev landscape that is more sophisticated, collaborative, and knowledge-driven than ever before. Infrastructure that improves visibility across partners and supports structured interaction within lifecycle networks, including platforms such as Scientist.com, is emerging alongside these shifts to help streamline the successful delivery of therapeutics from lab to patient.
Read the rest of the series: